• Explore /
  • Poster
  • / Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).

Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).

Abstract Poster

Authors

null

Suzanne Phillips

University of Texas MD Anderson Cancer Center, Houston, TX

Suzanne Phillips , Elizabeth M. Burton , Firas Y. Kreidieh , Isabella Claudia Glitza , Jennifer Leigh McQuade , Rodabe Navroze Amaria , Adi Diab , Sapna Pradyuman Patel , Michael K.K. Wong , Jing Li , Caroline Chung , Denai R. Milton , Jared Malke , Julie Simon , Jeffrey Scott Wefel , Michael A. Davies , Hussein A. Tawbi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05704647

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS9605)

DOI

10.1200/JCO.2023.41.16_suppl.TPS9605

Abstract #

TPS9605

Poster Bd #

361b

Abstract Disclosures

Similar Posters

First Author: Kim Allyson Margolin

First Author: Anna Maria Di Giacomo

First Author: Dirk Schadendorf

First Author: Zeynep Eroglu